东北制药拟开展不超3亿元金融衍生品交易以对冲汇率风险

Core Viewpoint - Northeast Pharmaceutical Group Co., Ltd. has announced plans to engage in financial derivatives trading to manage foreign exchange and interest rate risks arising from its foreign currency settlements in response to market fluctuations [1] Group 1: Financial Derivatives Trading - The primary objective of this trading initiative is hedging, aimed at locking in costs and avoiding risks rather than engaging in speculation or arbitrage [1] - The maximum trading amount is set at 300 million RMB, which can be rolled over within its validity period [1] - The trading instruments will mainly include forward foreign exchange settlements, currency swaps, options, interest rate swaps, and currency swaps, with trading periods generally not exceeding one year [1] Group 2: Financial Stability and Risk Management - The company emphasizes that all trading funds will come from its own capital and will collaborate with legally qualified domestic and foreign large commercial banks [1] - This initiative is viewed as a significant risk control measure to enhance financial stability and mitigate the potential adverse impacts of exchange rate and interest rate fluctuations on operational performance [1] - The company has established corresponding internal operational processes and risk control measures to prevent market, liquidity, and operational risks [1]